Spyre Therapeutics (SYRE): Favorite Stock of Elite Money Managers [Yahoo! Finance]
Spyre Therapeutics, Inc. (SYRE)
Company Research
Source: Yahoo! Finance
Following a string of clinical successes in early April, Spyre Therapeutics, Inc. (NASDAQ:SYRE) stock has become a favorite for managers looking to capitalize on the multi-billion dollar Inflammatory Bowel Disease market. A major catalyst for the shares was the recent announcement of Part A induction results from the Phase 2 SKYLINE trial for SPY001. The drug met its primary endpoint in patients with moderate-to-severe ulcerative colitis. The trial showed a 40% clinical remission rate at Week 12, which analysts from Goldman Sachs noted is potentially superior to currently available treatments like Entyvio. The data confirmed a pharmacokinetic profile that could allow for quarterly or even biannual subcutaneous dosing, a massive convenience advantage over the monthly or bi-monthly schedules of competitors. Spyre Therapeutics, Inc. (NASDAQ:SYRE) has a unique strategy of combining best-in-class antibodies. Beyond SPY001, Spyre is developing long-acting antibodies targeting TL1A and IL
Show less
Read more
Impact Snapshot
Event Time:
SYRE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SYRE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SYRE alerts
High impacting Spyre Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SYRE
News
- Spyre Therapeutics (SYRE) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=SYRE&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "holMarketBeat
- Here's What Raymond James Says About Spyre Therapeutics Inc (SYRE) [Yahoo! Finance]Yahoo! Finance
- Spyre Therapeutics (SYRE) had its price target raised by JonesTrading from $64.00 to $95.00. They now have a "buy" rating on the stock.MarketBeat
- Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 MillionGlobeNewswire
- Spyre Therapeutics (SYRE) Is Up 32.7% After $403 Million Equity Raise On Positive Phase 2 Data [Yahoo! Finance]Yahoo! Finance
SYRE
Earnings
- 11/4/25 - Beat
SYRE
Sec Filings
- 4/22/26 - Form SCHEDULE
- 4/20/26 - Form SCHEDULE
- 4/16/26 - Form 8-K
- SYRE's page on the SEC website